The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
"How I treat” based on the new/updated classification systems
Theo de Witte
Pierre Fenaux
Yasushi MiyazakiDuring the MDS Hub Steering Committee meeting, held on October 26, 2023, Pierre Fenaux chaired a “How I treat” discussion based on the new/updated classification systems in myelodysplastic syndromes (MDS), with contributions from Theo de Witte and Yasushi Miyazaki.
“How I treat” based on the new/updated classification systems
Fenaux highlights the differences between the 5th edition of the World Health Organization Classification of Hematolymphoid Tumors and the International Consensus Classification of Myeloid Neoplasms and Acute Leukemia, outlining the consequences of these differences in the management of MDS. He also discusses the Molecular International Prognostic Scoring System and the impact of a patient's mutational profile on treatment decision-making. Fenaux continues by describing the updates in the International Working Group 2023 response criteria for higher-risk (MDS). To conclude, the committee discusses factors that influence transplant decision-making and the use of azacitidine and venetoclax as a bridge to transplant.
